Nigeria plans to produce 70 per cent of its essential medicines locally by 2030, Minister of State for Health and Social Welfare Dr Iziaq Salako announced at the opening of the 8th Nigeria Pharma Manufacturers Expo in Lagos on Tuesday, 29 September 2026. Health authorities have combined a two-billion-dollar financing pipeline with targeted tariff waivers to lure drug makers into domestic factories and break a dangerous reliance on foreign suppliers. The state imports over seventy per cent of its retail pills today. Foreign supply shocks regularly clear shelves at local pharmacies.
To guarantee steady commercial off-take for these domestic factories, the federal health ministry set up Medipool, a national group purchasing organisation designed to aggregate medicine orders across public clinics and private hospitals. Salako urged domestic chemists to tap Africa’s rich botanical heritage, pointing out that the continent holds a quarter of the world’s medicinal plant genetic resources for scientific research and herbal development. Health planners hope guaranteed bulk purchasing will shield infant factories from cheap imported generics while regional integration under the African Continental Free Trade Area expands their export reach. Bold targets need reliable commercial buyers.
Yet industrial reality threatens to choke these grand ministerial ambitions before factory machines can turn out their first batch of sterile vials. Commercial banks still lend at punitive rates above twenty-five per cent, pricing local entrepreneurs entirely out of long-term capital investments. Running sensitive laboratory mixers on diesel generators burns through cash reserves that foreign rivals invest in clinical trials. Industrial medicine requires cheap electric currents.
Nigeria still imports nearly all the active pharmaceutical ingredients and chemical excipients required to press even a single basic paracetamol tablet. When the naira tumbled on foreign exchange desks, local drug prices jumped by four hundred per cent and exposed the country’s complete lack of upstream industrial synthesis. Assembling imported powder inside domestic capsules does not create genuine pharmaceutical sovereignty. Real autonomy demands chemical manufacturing first.
Industrial planners must fix base infrastructure, build dedicated chemical clusters, and tame borrowing costs before local factories can match low-cost Indian and Chinese producers. Lofty government speeches and public procurement pools will deliver very little if chronic power blackouts continue to wreck clean-room standards across industrial estates in Ikeja and Sango-Ota. Drug security depends on industrial execution rather than optimistic calendar goals. Good intentions cannot cure broken factory floors.